Effect of morphine and morphine plus apotel on pain status, hemodynamic parameters and drug side effects in patients with acute myocardial infarction

Comparative study of the effect of morphine and morphine plus Apotel on pain relief, hemodynamic status and drug side effects In patients with acute myocardial infarction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220119053760N1

Enrollment

Registered

2022-02-13

Start date

2019-01-21

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. Other current complications following acute myocardial infarction

Interventions

Intervention 1: Control group: 5 mg of morphine (manufactured by Darupakhsh Pharmaceutical Company in 10 mg ampoules with a volume of 1 ml) was diluted in 10 cc of distilled water and identified and u

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with chest pain and ECG changes indicating acute myocardial infarction or elevated ST segment, Age between 20 up to 80 years Patient consent

Exclusion criteria

Exclusion criteria: Contraindications to taking Apotel and Morphine (severe diarrhea, pseudomembranous choline, acute respiratory failure, drug sensitivity, liver disease) Drug addiction

Design outcomes

Primary

Measure	Time frame
Intensity of pain. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: The Visual Analogue Scale (VAS) was reported from zero (painless) to ten (maximum pain experienced).;Blood pressure. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Mercury blood pressure monitor in millimeters of mercury.;Heart rate. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Tethoscope counts heart rate (in minutes).;Blood oxygen saturation percentage. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Pulse oximeter.;Drug side effects. Timepoint: Times: 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Observe the patient's condition and ask the patient.	—

Measure

Time frame

Intensity of pain. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: The Visual Analogue Scale (VAS) was reported from zero (painless) to ten (maximum pain experienced).;Blood pressure. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Mercury blood pressure monitor in millimeters of mercury.;Heart rate. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Tethoscope counts heart rate (in minutes).;Blood oxygen saturation percentage. Timepoint: Times: zero (basal), 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Pulse oximeter.;Drug side effects. Timepoint: Times: 15 minutes later, 30 minutes later, 45 minutes later, 60 minutes after injection. Method of measurement: Observe the patient's condition and ask the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehrdad Esmailian

Esfahan University of Medical Sciences

m_esmailian@med.mui.ac.ir+98 31 3668 8597

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026